MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
MetaVia appointed Sarah Browne, M.D., as Chief Medical Officer, effective October 12, 2026. Dr. Browne brings 20+ years of liver and metabolic disease development experience, including leading pemvidutide (a dual GLP-1/glucagon agonist) at Altimmune through Phase 2 and a successful FDA End-of-Phase 2 meeting, plus prior FDA CBER review experience.
Key figures
- Years experience
- 20+
- Da1726 phase1 part3 readout
- Q4 2026 topline data, higher target doses 48 mg and 64 mg
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.